GRI Bio to Participate in the Virtual Investor Closing Bell Series
GRI Bio to Participate in the Virtual Investor Closing Bell Series
A live video webcast will be available on the Events page under the Investors section of the Company's website (gribio.com). A webcast replay will be available two hours following the live event and will be accessible for 90 days.Live webcast on Thursday, December 12th at 4:00 PM ET
2024年12月12日（星期四）東部時間下午4點進行現場直播網絡播出
LA JOLLA, CA, Dec. 06, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio will participate in the Virtual Investor Closing Bell Series on Thursday, December 12, 2024 at 4:00 PM ET.
加州拉荷亞，2024年12月06日（環球新聞社）- GRI生物公司（納斯達克：GRI）（"GRI生物" 或"公司"），一家生物技術公司，正在推進一系列創新的天然殺手T（"NKT"）細胞調節劑，用於治療炎症、纖維化和自身免疫疾病，今日宣佈，GRI生物首席執行官馬克·赫爾茨博士將於2024年12月12日星期四參加虛擬投資者收盤鍾系列活動，時間爲下午4:00。
As part of the event, Dr. Hertz will provide a corporate overview and business outlook. In addition to the moderated discussion, investors and interested parties will have the opportunity to submit questions live during the event. The Company will answer as many questions as possible in the time allowed.
作爲活動的一部分，Hertz博士將提供公司的概述和業務前景。除了主持討論外，投資者和感興趣的人士將在活動期間有機會實時提交問題。公司將在允許的時間內儘可能多地回答問題。
A live video webcast will be available on the Events page under the Investors section of the Company's website (gribio.com). A webcast replay will be available two hours following the live event and will be accessible for 90 days.
公司網站（gribio.com）投資者部分的活動頁面上將提供現場直播視頻網絡播出。直播結束後兩個小時內將提供網絡播回放，並可訪問90天。
About GRI Bio, Inc.
關於GRI Bio, Inc.
GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio's therapies are designed to target the activity of NKT cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type 1 invariant (iNKT) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio's lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 NKT agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.
GRI Bio是一家臨床階段的生物製藥公司，專注於從根本上改變炎症，纖維化和自身免疫性疾病的治療方式。 GRI Bio的治療療法旨在針對NKT細胞的活性，這些細胞是炎症級聯中早期的關鍵調節因子，以阻斷疾病進程並恢復免疫系統的穩態。 NKT細胞是一種類似本能型t細胞的細胞，它們具有Nk細胞和t細胞的特性，是本能型和適應性免疫反應之間的功能鏈接。類型1不變（iNKT）細胞在炎症和纖維化症狀中起着傳播損傷，炎症反應和纖維化的關鍵作用。 GRI Bio的領先項目GRI-0621是iNKt細胞活性的抑制劑，正在開發中作爲治療特發性肺纖維化的新型口服療法，該疾病極具需求。 該公司還在開發一系列用於系統性紅斑狼瘡治療的新型第二代NKt激動劑。 此外，憑藉超過500種專有化合物的庫，GRI Bio具有推動日益增長的管道的能力。
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
GRI@jtcir.com
投資者聯繫人：
JTC Team，LLC
Jenene Thomas
(908) 824-0775
GRI@jtcir.com
譯文內容由第三人軟體翻譯。